Dermira (NASDAQ:DERM) shares traded up 5.3% during trading on Monday . The stock traded as high as $8.58 and last traded at $8.50. 848,116 shares were traded during mid-day trading, a decline of 44% from the average session volume of 1,520,827 shares. The stock had previously closed at $8.07.
Several research analysts recently commented on the stock. Cantor Fitzgerald set a $20.00 target price on shares of Dermira and gave the stock a “buy” rating in a report on Monday, April 9th. BidaskClub downgraded shares of Dermira from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 10th. Leerink Swann lifted their target price on shares of Dermira from $42.00 to $48.00 and gave the stock an “outperform” rating in a report on Wednesday, January 17th. Finally, Guggenheim downgraded shares of Dermira from a “buy” rating to a “neutral” rating in a report on Tuesday, March 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $32.71.
The company has a debt-to-equity ratio of 1.87, a quick ratio of 5.28 and a current ratio of 5.28. The firm has a market capitalization of $355.49, a PE ratio of -1.97 and a beta of 1.52.
Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.09). Dermira had a negative return on equity of 62.07% and a negative net margin of 6,678.29%. The company had revenue of $1.34 million for the quarter, compared to the consensus estimate of $1.10 million. equities analysts forecast that Dermira will post -4.81 earnings per share for the current year.
In other news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $28.55, for a total transaction of $85,650.00. Following the transaction, the insider now owns 5,802 shares in the company, valued at approximately $165,647.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 4,700 shares of company stock worth $131,142. Insiders own 13.30% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Millennium Management LLC bought a new position in shares of Dermira during the 4th quarter worth about $25,084,000. Franklin Resources Inc. acquired a new stake in shares of Dermira during the 4th quarter valued at about $24,820,000. Emerald Advisers Inc. PA acquired a new stake in shares of Dermira during the 4th quarter valued at about $14,918,000. Rock Springs Capital Management LP boosted its position in shares of Dermira by 5.0% during the 4th quarter. Rock Springs Capital Management LP now owns 420,000 shares of the biopharmaceutical company’s stock valued at $11,680,000 after acquiring an additional 20,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Dermira by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 326,223 shares of the biopharmaceutical company’s stock valued at $9,072,000 after acquiring an additional 15,163 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Dermira (DERM) Trading 5.3% Higher” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/18/dermira-derm-trading-5-3-higher.html.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.